Sankyo Co., Ltd. provided updated consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 155,000 million as compared to previous JPY 135,000 million, operating profit to be JPY 55,000 million, as compared to previous JPY 45,000 million, profit attributable to owners of parent to be JPY 45,000 million as compared to previously announced JPY 35,000 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,633 JPY | -1.98% | -1.21% | -0.71% |
Apr. 08 | AstraZeneca hails neurological data for Ultomiris, Soliris | AN |
Apr. 08 | AstraZeneca's, Daiichi's Enhertu receives US FDA approval | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.71% | 2.36B | |
+13.93% | 8.46B | |
-23.96% | 718M | |
+10.12% | 695M | |
+31.17% | 367M | |
+3.44% | 342M | |
+4.63% | 340M | |
+16.30% | 188M | |
+27.77% | 101M | |
-28.70% | 62.86M |
- Stock Market
- Equities
- 6417 Stock
- News Sankyo Co., Ltd.
- Sankyo Co., Ltd. Updates Consolidated Earnings Guidance for the Year Ending March 31, 2023